Table 4.
Subset of Pathways Associated with the 197 Genes Differentially Expressed (≥2-Fold Difference, P≤0.01) Between the Intermediate and Outer Interzones with Specific Focus on Those Pathways That Have Known Relevance for the Musculoskeletal System or Inflammation
| Ingenuity canonical pathways | −Log (P-value) | P-value | Ratio | Molecules |
|---|---|---|---|---|
| Musculoskeletal pathways | ||||
| Human embryonic stem cell pluripotency | 3.89 | 1.29E-04 | 0.051 | FGFR3, BMPR1B, BMP2, WNT4, PIK3CD, BMP5, PDGFB, WNT5B |
| Role of NANOG in mammalian embryonic stem cell pluripotency | 2.83 | 1.48E-03 | 0.053 | BMPR1B, BMP2, WNT4, PIK3CD, BMP5, WNT5B |
| Wnt/β-catenin signaling | 2.52 | 3.02E-03 | 0.040 | SOX9, FRZB, SFRP5, WNT4, CCND1, RARG, WNT5B |
| Sonic hedgehog signaling | 2.49 | 3.24E-03 | 0.091 | PTCH1, HHIP, GLIS1 |
| Role of osteoblasts, osteoclasts, and chondrocytes in rheumatoid arthritis | 2.47 | 3.39E-03 | 0.034 | BMPR1B, FRZB, BMP2, SFRP5, WNT4, PIK3CD, BMP5, WNT5B |
| BMP signaling pathway | 1.34 | 4.57E-02 | 0.038 | BMPR1B, BMP2, BMP5 |
| Inflammatory pathways | ||||
| FcγRIIB signaling in B lymphocytes | 2.91 | 1.23E-03 | 0.068 | BLNK, BTK, LYN, PIK3CD |
| IL-9 signaling | 2.20 | 6.31E-03 | 0.075 | IL9R, BCL3, PIK3CD |
| Atherosclerosis signaling | 2.05 | 8.91E-03 | 0.037 | PLB1, COL2A1, ALOX12, ALOX5, PDGFB |
| Role of JAK1 and JAK3 in γc cytokine signaling | 1.50 | 3.16E-02 | 0.045 | BLNK, IL9R, PIK3CD |
| B cell receptor signaling | 1.48 | 3.31E-02 | 0.029 | BLNK, BTK, EBF1, LYN, PIK3CD |
| NF-κB signaling | 1.48 | 3.31E-02 | 0.029 | FGFR3, BMPR1B, BMP2, FLT4, PIK3CD |
| GM-CSF signaling | 1.46 | 3.47E-02 | 0.044 | LYN, PIK3CD, CCND1 |
| Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis | 1.36 | 4.37E-02 | 0.021 | FRZB, SFRP5, WNT4, PIK3CD, CCND1, PDGFB, WNT5B |
The list is sorted by statistical significance. The column “Molecules” lists the differentially expressed genes of our experimental dataset, which are categorized into the respective pathways. The column “Ratio” indicates the number of experimental genes partaking in the pathway divided by the total number of genes known to participate in the pathway.
BMP, bone morphogenetic protein; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL-9, interleukin-9; NF-κB, nuclear-factor κB.